dm+d

Unassigned

New Medicines

Early Alzheimer's disease (MCI and mild) and moderate

Information

New molecular entity
TauRx Pharmaceuticals
TauRx Pharmaceuticals

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A second‐generation Tau Aggregation Inhibitor (TAI) that targets Tau tangles and their precursors, Tau aggregates (called ‘oligomers’).
There are an estimated 600,000-650,000 people with dementia in England and Wales, with an estimated 35-60% being of the Alzheimer’s type (equating to between 210,000 and 390,000 people). Alzheimer’s disease progression is dependent on age, with a time from diagnosis to death of about 5−20 years, and a median survival from onset of dementia to death of 7.1 years. NICE estimated that 50−64% of people with Alzheimer’s disease have mild to moderate disease [3]
Early Alzheimer's disease (MCI and mild) and moderate
Oral

Behavioural variant frontotemporal dementia (Picks disease)

Information

Licence extension / variation
TauRx Pharmaceuticals
TauRx Pharmaceuticals

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Tau protein inhibitor
Behavioural variant frontotemporal dementia affects ~ 1.5 in 10,000 people in the EU; equivalent to around 76,000 people [2]
Behavioural variant frontotemporal dementia (Picks disease)
Oral

Evidence based evaluations